Novartis announced Thursday it will pay $422.5 million to settle criminal and civil allegations that it marketed several drugs for unapproved uses. Under the settlement, Novartis will plead guilty to one misdemeanour count of misbranding its Trileptal seizure medication and pay a fine of $185 million. The drugmaker will pay a further $237.5 million to settle civil allegations related to the marketing of Trileptal and five other drugs.
Reference Articles
Novartis to pay $422.5 million to end Trileptal probes - (Bloomberg)
Novartis agrees to $422.5 mln marketing fine - (MarketWatch)
Novartis Pharmaceuticals, a US subsidiary of Novartis, reaches settlement agreement with US Attorney's Office - (Novartis)
**Published by "First Word"
Diario digital con noticias de actualidad relacionadas con el mundo de la salud. Novedades, encuestas, estudios, informes, entrevistas. Con un sencillo lenguaje dirigido a todo el mundo. Y algunos consejos turísticos para pasarlo bien
Traductor
30 September 2010
Novartis to pay $422.5 million to settle criminal, civil charges related to drug marketing
Subscribe to:
Post Comments (Atom)
CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies
Copyright © Noticia de Salud
No comments:
Post a Comment